Why Microsoft Shares Are Falling

Microsoft Corporation (NASDAQ: MSFT) shares are trading lower by 2.27% to $235.60 Thursday morning amid overall market weakness. Shares of companies in the broader tech sector are trading lower amid a rise in treasury yields.

Microsoft Corporation (NASDAQ:MSFT) shares are trading lower by 2.27% to $235.60 Thursday morning amid overall market weakness. Shares of companies in the broader tech sector are trading lower amid a rise in treasury yields. The weakness in the overall market may also be weighing on the sector following Jobless claims for September that came in below estimates, which has added to concerns of further Fed action to curb the tight labor market.

What Happened?

U.S. initial jobless claims unexpectedly fell last week to the lowest levels since April, signaling the labor market remains resilient despite continued rate hikes from the Federal Reserve.

Jobless claims decreased by 16,000 for the week ending Sept. 24 to 193,000 from a downwardly revised level of 209,000 in the prior week, according to data the Labor Department released on Thursday…Read More

See Also: Surprise! Jobless Claims Fall To Lowest Levels Since April: What You Need To Know Now

According to data from Benzinga Pro, Microsoft has a 52-week high of $349.67 and a 52-week low of $234.41.

Total
0
Shares
Related Posts
Read More

Insiders Buying Asana And 2 Other Stocks

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

ASAN

Read More

What’s Going On With ImmunityBio Stock?

ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy. 

IBRX